Alnylam Pharmaceuticals, Inc. vs Fabrinet — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.94 (market cap $29.60B), while Fabrinet trades at $581.02 (market cap $18.84B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Fabrinet is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FN | |
|---|---|---|
Market Cap | $29.60B | $18.84B |
Sector | Health | Technology |
52-Week High | $491.22 | $746.47 |
52-Week Low | $205.48 | $277.04 |
Enterprise Value | $27.56B | $17.90B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Fabrinet (FN) trades at $583.95, up 10.79% in 24 hours, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42 billion in 2025, with a net income margin of 9.94%, while the company maintains a debt-free balance sheet and strategic positioning in AI optical supply chains.
Outlook is positive due to robust AI-driven demand and expansion plans, though risks include premium valuation (P/E 45.18) and supply chain constraints. Analysts are bullish with 75% buy ratings and a $661.75 price target (MarketBeat, 2026-07-07), but technical indicators suggest near-term resistance near $532.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →